IPO Date: Dec 1 to Dec 3 2025
Listing Date: Dec 8 2025
1. Marketing and advertisement expenses toward enhancing the awareness and visibility of our brand
2. Setting up a new manufacturing facility at Mauje-Peth in Amravati (“Proposed facility”)
3. General corporate purposes
12th Floor, Flat 1211, 9 Business Bay Khakhar Property, Off New Link Road Mindspace Behind Evershine Mall, Chincholi Bunder, Malad (W)
Mumbai
Maharashtra
400064
8433980120
esha@ravelcare.com
www.ravelcare.com
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Ravelcare has informed that 8th Annual General Meeting of the company was held on Wednesday, September 23, 2026 through Video Conferencing (VC)/Other Audio-Visual Means (OAVM) in compliance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. A disclosure of voting results of the meeting in terms of Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the businesses considered and approved by the shareholders is enclosed, together with the Scrutinizer's Report on e-voting. A copy of the same is also being placed on the Company's website www.ravelcare.com.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Rubicon Research has informed that the United States Food and Drug Administration (US FDA) conducted an unannounced inspection (triggered by a product filing) of the company’s manufacturing facility located at Plot No. K30/4 & 30/5, Additional M.I.D.C., Anand Nagar, Ambernath, Maharashtra, India from Wednesday, 21 October 2026 to Thursday, 29 October 2026. This was a comprehensive GMP inspection in addition to the product application under review. Upon conclusion, a Form 483 containing 3 observations with respect to system improvement and 2 observations with respect to product application under review were issued, all 5 of which are procedural in nature and do not relate to data integrity. The company is confident of working closely with the regulator to successfully conclude the evaluation in a timely manner. All its manufacturing as well as R&D facilities have now been inspected by the US FDA in the recent past and it has enclosed the status of all its operational facilities.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Fabtech Technologies has informed that it enclosed the Investor Presentation in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026.
The above information is a part of company’s filings submitted to BSE.
With reference to the clarification dated October 27, 2026, regarding the significant movement in the price of the securities of the Company, NMS Global has submitted: The Company is not aware of any undisclosed material event, information, or development that would require disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which could have a bearing on the movement in the price of its securities. The Company has been making disclosures to the Stock Exchanges from time to time in accordance with the applicable provisions of the SEBI (LODR) Regulations, 2015. The Company remains committed to ensuring timely disclosure of all material information and maintaining transparency with its shareholders and the investing public. The movement in the price of the Company's securities appears to be market-driven, and the Company is not in a position to comment on the specific reasons for such movement. The company has confirmed that, should any material event or information requiring disclosure arise, the Company shall make the requisite disclosure to the Stock Exchanges in accordance with applicable regulatory requirements.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The issue size of Ravelcare Ltd. IPO is ₹16.35 - 17.28 crore.
The Ravelcare Ltd. IPO opens for subscription on 2025-12-01 and closes on 2025-12-03.
The price range of Ravelcare Ltd. IPO is ₹123.00 to ₹130.00.
The lot size of Ravelcare Ltd. IPO is 2000 shares.
The registrar of Ravelcare Ltd. IPO is K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.).
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.